<listing id="pbjlx"><progress id="pbjlx"><sub id="pbjlx"></sub></progress></listing>

        <ol id="pbjlx"></ol>

          1 / 3

          About Ribo

          Established in 2007, Suzhou Ribo Life Science Co. Ltd. is devoted to the advanced oligonucleotide therapeutics in China including siRNA, antisense and aptamer drugs based on proprietary intellectual properties. The core members of the R&D team include top experts in the fields of siRNA biotechnology, nucleic acid chemistry, drug delivery and development, consisting of both overseas returnees and domestic scientists. Ribo is committed to promoting siRNA and other RNA drugs, as well as technology innovation, in order to deliver more precise and efficient therapies to the patients worldwide.

          Technological Innovations

          Ribo continues to promote innovation of drugs development and the manufacturing process and has established an integrated drug R&D system covering drug design, target validation, drug delivery, quality study, pharmacological, toxicological, and pharmacokinetic evaluation, synthesis of monomers and oligonucleotides, and clinical study.

          siRNA delivery technology platform

          Oligonucleotide modification for enhanced stability platform

          Oligonucleotide therapeutic bioanalysis platform

          CMC Development of Oligonucleotide platform

          Oligonucleotide monomer platform

          Oligonucleotide sequence design and high-throughput screening platform

          Pipeline

          Driven by independent innovation and international cooperation, Ribo has built up robust R&D pipelines for oligonucleotide targeted at a number of therapeutic areas, such as ophthalmic diseases, metabolic diseases,central nervous system diseases, cancer, and liver diseases, in addition to anti-virus treatment.

          SR061

          NAION

          SR062

          Type 2 Diabetes

          SR063

          Prostate Cancer

          SR016

          Hepatitis B

          SR060

          Thrombotic Diseases

          SR043

          Hyperlipidemia

          <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <蜘蛛词>| <文本链> <文本链> <文本链> <文本链> <文本链> <文本链>